NCT06080464 Clinician Satisfaction With the VERABAND™
| NCT ID | NCT06080464 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Chronic Low-back Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 360 participants |
| Start Date | 2025-06-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 360 participants in total. It began in 2025-06-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The VERABAND™ is a newly-developed, disposable, wearable activity monitor. The researchers will assess clinician satisfaction with the usability and likelihood of clinical adoption of the newly-developed, disposable, wearable activity monitor, across multiple clinical sites in the chronic low back pain (cLBP) population.
Eligibility Criteria
Any treating clinician at a recruiting tertiary pain clinic will be eligible to participate. Patient participants must meet the following criteria: Inclusion Criteria: * Ambulatory * Diagnosis of chronic low back pain (cLBP) according to the criteria of National Institute of Health (NIH) Task Force on Research Standards for cLBP * Answering 'Yes' to the question: Does your low back pain interfere with your mobility? * Starting any new non-surgical treatment or combination of treatments for cLBP as part of their normal ongoing care, including medications; physical therapy/exercise; integrated therapies (e.g., massage, acupuncture, yoga); cognitive- behavioral therapy; and/or interventional procedures (e.g., epidural steroid or facet joint injections) * Willingness to wear a VERABAND™ continuously until their next clinic visit and return used devices in the mail. Exclusion Criteria: * Clinical findings suggesting the presence of ongoing systemic disease, including fever, weight loss, initiation of pain following major trauma, immunosuppression, intravenous drug use, recent bacterial infection, severe or persistent sensory or motor involvement of bowel, bladder, or lower extremity; or any condition that would greatly limit physical activity not due to pain. * Inability to speak and write English. * Visual or hearing difficulties that would preclude participation. * Severe psychiatric disorders that in the opinion of the investigative team would interfere with participation in the study. This includes any active suicidal ideations or history of suicide attempts. Exclusions will be based on self-reported medical history or chart review and in accordance with Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. * Individuals receiving disability or compensation or involved in litigation. * Scheduled surgery before follow-up.
Contact & Investigator
Daniel Whibley, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT06080464 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Chronic Low-back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06080464 currently recruiting?
Yes, NCT06080464 is actively recruiting participants. Contact the research team at knpicku@med.umich.edu for enrollment information.
Where is the NCT06080464 trial being conducted?
This trial is being conducted at La Jolla, United States, Kansas City, United States, Ann Arbor, United States.
Who is sponsoring the NCT06080464 clinical trial?
NCT06080464 is sponsored by University of Michigan. The principal investigator is Daniel Whibley, PhD at University of Michigan. The trial plans to enroll 360 participants.